Investigation on correlation between expression of CD58 molecule and severity of hepatitis B

Li, Sheng; Li, Jie; Qi, Bao-tai; Ji, Yibing; Meng, Zhaojun; Xie, Ming

doi:10.3748/wjg.v12.i26.4237

Cited by 6 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of CD58 in hepatocytes of chronic hepatitis exhibits cytoplasmic and membranous staining and elevated with the severity of chronic HBV infection, the degree of inflammatory activity, and liver damage ( 177 – 179 ). More importantly, the proportion of CD58 + cells in peripheral blood mononuclear cells and the levels of sCD58 in serum of patients with HBV infection are conspicuously higher than that in the healthy individuals and positively associated with serum levels of AST and ALT ( 178 , 179 ). These findings demonstrate that CD2-CD58 interactions between lymphocytes and hepatocytes exert an essential function in chronic hepatitis ( 177 ).…”

Section: Chronic Hepatitismentioning

confidence: 99%

See 1 more Smart Citation

CD58 Immunobiology at a Glance

et al. 2021

View full text Add to dashboard Cite

The glycoprotein CD58, also known as lymphocyte-function antigen 3 (LFA-3), is a costimulatory receptor distributed on a broad range of human tissue cells. Its natural ligand CD2 is primarily expressed on the surface of T/NK cells. The CD2-CD58 interaction is an important component of the immunological synapse (IS) that induces activation and proliferation of T/NK cells and triggers a series of intracellular signaling in T/NK cells and target cells, respectively, in addition to promoting cell adhesion and recognition. Furthermore, a soluble form of CD58 (sCD58) is also present in cellular supernatant in vitro and in local tissues in vivo. The sCD58 is involved in T/NK cell-mediated immune responses as an immunosuppressive factor by affecting CD2-CD58 interaction. Altered accumulation of sCD58 may lead to immunosuppression of T/NK cells in the tumor microenvironment, allowing sCD58 as a novel immunotherapeutic target. Recently, the crucial roles of costimulatory molecule CD58 in immunomodulation seem to be reattracting the interests of investigators. In particular, the CD2-CD58 interaction is involved in the regulation of antiviral responses, inflammatory responses in autoimmune diseases, immune rejection of transplantation, and immune evasion of tumor cells. In this review, we provide a comprehensive summary of CD58 immunobiology.

show abstract

Section: Chronic Hepatitismentioning

confidence: 99%

“…Immune adhesion molecule CD58 may strengthen viral elimination via activating T/NK cells and stimulating the cytotoxic immune response. Unfortunately, this also causes the damage of hepatocytes ( 179 ).…”

Section: Chronic Hepatitismentioning

confidence: 99%

CD58 Immunobiology at a Glance

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The previous study suggested that sCD58 levels in the serum of HBV-infected patients are substantially higher than in the normal population and correlate with disease severity [ 47 ]. The majority of HCC occurs in the presence of chronic liver disease and cirrhosis, for which hepatitis is the leading cause [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway

Wang,

Cao,

Cao

et al. 2023

J Transl Med

View full text Add to dashboard Cite

Background Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide because of rapid progression and high incidence of metastasis or recurrence. Accumulating evidence shows that CD58-expressing tumor cell is implicated in development of various cancers. The present study aimed to reveal the functional significance of CD58 in HCC progression and the underlying mechanisms. Methods Immunohistochemical staining (IHC), and western blotting were used to detect the expression of CD58 in HCC tissues and cells. The levels of sCD58 (a soluble form of CD58) in the cell supernatants and serum were assessed by ELISA. CCK-8, colony formation, and xenograft assays were used to detect the function of CD58 on proliferation in vitro and in vivo. Transwell assay and sphere formation assay were performed to evaluate the effect of CD58 and sCD58 on metastasis and self-renewal ability of HCC cells. Western blotting, immunofluorescence (IF), TOP/FOP Flash reporter assay, and subcellular fractionation assay were conducted to investigate the molecular regulation between CD58/sCD58 and AKT/GSK-3β/β-catenin axis in HCC cells. Results CD58 was significantly upregulated in HCC tissues. Elevation of CD58 expression correlated with more satellite foci and vascular invasion, and poorer tumor-free and overall survival in HCC patients. Higher sCD58 levels were in HCC patients' serum compared to healthy individuals. Functionally, CD58 promotes the proliferation of HCC cells in vitro and in vivo. Meanwhile, CD58 and sCD58 induce metastasis, self-renewal and pluripotency in HCC cells in vitro. Mechanistically, CD58 activates the AKT/GSK-3β/β-catenin signaling pathway by increasing phosphorylation of AKT or GSK3β signaling, promoting expression of Wnt/β-catenin target proteins and TCF/LEF-mediated transcriptional activity. Furthermore, AKT activator SC-79 or inhibitor LY294002 abolished the inhibitory effect of CD58 silencing on the proliferation, metastasis, and stemness of HCC cells. Conclusions Taken together, CD58 promotes HCC progression and metastasis via activating the AKT/GSK-3β/β-catenin pathway, suggesting that CD58 is a novel prognostic biomarker and therapeutic target for HCC. Graphical Abstract

show abstract

“…It is expressed on the surface of B cells, T cells, monocytes, granulocytes and thymic epithelial cells. It is an important adhesion molecule in cells [20,21]. The ligand of CD58, CD2, also known as T11 and LFA-2, is the erythrocyte (E) rosette receptor.…”

Section: Introductionmentioning

confidence: 99%

CD58 as a biomarker for prognosis and immune infiltration in hepatocellular carcinoma

Cai

Chen

Wang

et al. 2022

Preprint

View full text Add to dashboard Cite

BACKGROUND The glycoprotein CD58, is a co-stimulatory receptor distributed on a wide range of human tissue cells. CD2 interacts with CD58 to promote important adhesion between T cells and target cells and to induce signaling events involved in the regulation of T cell responses. However, the relevance of CD58 to the prognosis of different tumors and to tumor-infiltrating lymphocytes is unclear. RESULTS Analysis of CD58 expression through the Tumor Immune Evaluation Resource (TIMER) website and UALCAN, revealed meaningful differential expression of CD58 between hepatocellular carcinoma (LIHC) tumor tissue and normal tissue, with higher levels of CD58 expression in hepatocellular carcinoma than in normal tissue. We used Kaplan-Meier plotter and gene expression profiling interaction analysis (GEPIA) to assess the impact of CD58 on clinical prognosis and found that high CD58 expression was associated with a poorer prognosis in hepatocellular carcinoma. The correlation between CD58 and tumor immune infiltration by TIMER revealed that CD58 expression was negatively correlated with tumor purity and positively correlated with the level of immune infiltration of B cell, Neutrophil, Macrophage, Myeloid dendritic cell and T cell CD4+. Furthermore, we analyzed the correlation between CD58 expression and the gene marker sets for immune infiltration using TIMER and GEPIA and found that in hepatocellular carcinoma, the expression levels of most monocytes, TAM, M1 macrophages, M2 macrophages, dendritic cells, Th1, Th2 and Treg marker sets correlated strongly with CD58 expression in LIHC. CONCLUSION CD58 is associated with the level of immune infiltration and prognosis of B cell, Neutrophil, Macrophage, Myeloid dendritic cell, T cell CD4 + in a variety of tumors, especially in patients with hepatocellular carcinoma. In addition, CD58 expression may help regulate the expression levels of most monocytes, TAM, M1 macrophages, M2 macrophages, dendritic cells, Th1, Th2, and Treg marker groups in hepatocellular carcinoma. It is suggested that CD58 may be used as a biomarker to determine the prognosis and immune infiltration of hepatocellular carcinoma.

show abstract

Investigation on correlation between expression of CD58 molecule and severity of hepatitis B

Abstract: The level of CD58 molecule (in both serum and PBMC form) of patients with hepatitis B is related to the degree of liver damage.

Cited by 6 publications

References 20 publications

CD58 Immunobiology at a Glance

CD58 Immunobiology at a Glance

CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway

CD58 as a biomarker for prognosis and immune infiltration in hepatocellular carcinoma

Contact Info

Product

Resources

About